NS Partners Ltd Sells 69,213 Shares of Boston Scientific Corporation $BSX

NS Partners Ltd trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 19.3% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 289,367 shares of the medical equipment provider’s stock after selling 69,213 shares during the period. NS Partners Ltd’s holdings in Boston Scientific were worth $12,350,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of BSX. CYBER HORNET ETFs LLC increased its position in Boston Scientific by 3.4% during the 3rd quarter. CYBER HORNET ETFs LLC now owns 4,004 shares of the medical equipment provider’s stock valued at $391,000 after purchasing an additional 132 shares during the period. Gerber Kawasaki Wealth & Investment Management lifted its position in shares of Boston Scientific by 4.7% in the 4th quarter. Gerber Kawasaki Wealth & Investment Management now owns 3,082 shares of the medical equipment provider’s stock worth $294,000 after purchasing an additional 139 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its stake in shares of Boston Scientific by 0.3% in the 4th quarter. Northwestern Mutual Investment Management Company LLC now owns 47,366 shares of the medical equipment provider’s stock valued at $4,516,000 after purchasing an additional 140 shares during the last quarter. Kingsview Wealth Management LLC increased its position in shares of Boston Scientific by 2.4% during the fourth quarter. Kingsview Wealth Management LLC now owns 6,066 shares of the medical equipment provider’s stock worth $578,000 after buying an additional 142 shares during the period. Finally, Fairfield Financial Advisors LTD raised its stake in Boston Scientific by 2.9% during the fourth quarter. Fairfield Financial Advisors LTD now owns 5,366 shares of the medical equipment provider’s stock worth $512,000 after buying an additional 150 shares during the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of brokerages have commented on BSX. Royal Bank Of Canada cut their price target on shares of Boston Scientific from $85.00 to $70.00 and set an “outperform” rating on the stock in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a $60.00 price objective on shares of Boston Scientific in a research note on Thursday, July 30th. Citigroup decreased their target price on Boston Scientific from $70.00 to $61.00 and set a “buy” rating for the company in a research note on Thursday, July 30th. Zacks Research downgraded Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $65.00 price target on shares of Boston Scientific in a research note on Friday, June 12th. Twenty-four analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Insiders Place Their Bets

In other Boston Scientific news, Director David C. Habiger bought 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 5th. The stock was bought at an average cost of $47.59 per share, with a total value of $99,939.00. Following the completion of the transaction, the director directly owned 17,160 shares in the company, valued at approximately $816,644.40. The trade was a 13.94% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Edward J. Ludwig bought 5,000 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was acquired at an average price of $45.48 per share, for a total transaction of $227,400.00. Following the acquisition, the director directly owned 30,359 shares in the company, valued at $1,380,727.32. The trade was a 19.72% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 194,522 shares of company stock worth $9,385,210. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Up 3.2%

BSX stock opened at $48.35 on Tuesday. The stock’s 50 day simple moving average is $46.65 and its 200 day simple moving average is $56.35. The company has a market cap of $70.07 billion, a P/E ratio of 19.57, a price-to-earnings-growth ratio of 1.02 and a beta of 0.56. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.74 and a current ratio of 1.24. Boston Scientific Corporation has a fifty-two week low of $42.20 and a fifty-two week high of $109.50.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.86 EPS for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a return on equity of 19.28% and a net margin of 17.50%.The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the previous year, the company posted $0.75 earnings per share. The company’s quarterly revenue was up 7.5% on a year-over-year basis. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, research analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific announced that its Board of Directors has approved a stock repurchase program on Monday, May 18th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase programs are typically an indication that the company’s leadership believes its stock is undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.